A5197: A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Hypothesis: The week 12 and week 16 post-ART interruption geometric mean HIV-1 RNA levels will be lower among subjects who had received MRK Ad5 vaccine prior to ART interruption than among subjects who received placebo. The time average area under the curve of the Log10 HIV-1 RNA copies/mL versus day function in the 16 week post-ART interruption step will be lower among subjects who receive the MRK Ad5 vaccine prior to ART interruption than among subjects who receive placebo.